Patients’ perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison

To compare, in patients with non‐muscle‐invasive low‐grade (pTa/pT1, G1/G2) urothelial cell carcinoma of the urinary bladder, the perceived burden of flexible cystoscopy or surveillance by microsatellite analysis (MA) in voided urine, as such patients are normally recommended to adhere to regular cysto‐urethroscopic surveillance (CUS).

[1]  H. D. de Koning,et al.  Women's acceptance of MRI in breast cancer surveillance because of a familial or genetic predisposition. , 2006, Breast.

[2]  E W Steyerberg,et al.  The burden of upper gastrointestinal endoscopy in patients with Barrett's esophagus. , 2006, Endoscopy.

[3]  L. Kiemeney,et al.  Current practice in the management of superficial bladder cancer in the Netherlands and Belgian Flanders: a survey. , 2006, European urology.

[4]  T. Ratliff.  Urine markers for bladder cancer surveillance: a systematic review. , 2005, The Journal of urology.

[5]  Y. Ceylan,et al.  Evaluation of Pain Caused by Urethrocystoscopy in Patients with Superficial Bladder Cancer: A Perspective of Quality of Life , 2005, Oncology Research and Treatment.

[6]  P. Mariappan,et al.  A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. , 2005, The Journal of urology.

[7]  K. Yoshimura,et al.  Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey. , 2005, Urology.

[8]  N. Sengupta,et al.  Cancers of the bladder , 2004, The journal of the Royal Society for the Promotion of Health.

[9]  Alberto Redaelli,et al.  The health economics of bladder cancer: a comprehensive review of the published literature. , 2003, PharmacoEconomics.

[10]  O. Cussenot,et al.  Non‐invasive molecular detection of bladder cancer recurrence , 2002, International journal of cancer.

[11]  T. H. van der Kwast,et al.  Microsatellite analysis—DNA test in urine competes with cystoscopy in follow‐up of superficial bladder carcinoma , 2001, Cancer.

[12]  H. Herr,et al.  Outpatient flexible cystoscopy in men: a randomized study of patient tolerance. , 2001, The Journal of urology.

[13]  L. Kiemeney,et al.  Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis. , 2000, Urology.

[14]  M. Essink‐bot,et al.  Why do men refuse or attend population-based screening for prostate cancer? , 2000, Journal of public health medicine.

[15]  M. Wright,et al.  Surveillance for bladder cancer: the management of 4.8 million people , 2000, BJU international.

[16]  Floratos,et al.  The tolerability of urodynamic studies and flexible cysto‐urethroscopy used in the assessment of men with lower urinary tract symptoms , 1999, BJU international.

[17]  H. D. de Koning,et al.  Short-term effects of population-based screening for prostate cancer on health-related quality of life. , 1998, Journal of the National Cancer Institute.

[18]  B. Têtu,et al.  The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. , 1998, British journal of urology.

[19]  Y S Erozan,et al.  Molecular Detection of Primary Bladder Cancer by Microsatellite Analysis , 1996, Science.

[20]  R. Sylvester,et al.  Factors affecting recurrence and progression in superficial bladder tumours. , 1995, European journal of cancer.

[21]  L. Kessler,et al.  Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at Diagnosis , 1995, Medical care.

[22]  G. Chisholm,et al.  Morbidity following cystoscopy: comparison of flexible and rigid techniques. , 1990, British journal of urology.